You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫療(01515.HK)全年綜合營業額升逾三成至27.51億元 末期息8.82港仙
格隆匯 03-26 23:59

格隆匯 3 月 26日丨華潤醫療(01515.HK)發佈截至2020年12月31日止年度全年業績公吿,集團共實現綜合營業額人民幣27.51億元(2019財政年度:人民幣21.15億元),同比增長30.03%。相關的增長主要因收購濟南重汽醫院及並表多家醫院而產生。惟報吿期內錄得淨利潤為人民幣3.20億元,母公司擁有人應占年度利潤為人民幣3.10億元。基本每股盈利人民幣0.25元,建議每股末期股息每股8.82港仙。

截至2020年12月31日,集團在中國9個省、市共管理運營107家醫療機構,集團成員醫院年度門診量和住院量分別為約770.6萬和22.0萬人次。受到新冠病毒疫情影響,在年初完成了對濟南重汽醫院收購的情況下,報吿期內集團成員醫院的醫療業務總收入為人民幣約66.44億元,業務經營情況已自2020年5月份開始顯著恢復。

2021年是“十四五”開局之年,集團將堅持以醫療服務為主業,聚焦佈局優勢專科、並明確專科連鎖集羣轉型的發展定位。在業務發展方面,集團將以專科連鎖醫院與綜合醫院為雙翼,在地域上將深耕京津冀,長三角和大灣區,併兼顧重點城市羣,透過資本運營和市場機制為雙引擎以構建醫療服務產業和資本運營良性融合的發展模式。在專科發展方面,集團亦將繼續強化臨牀能力、構建連鎖專科業務、創造更優質品牌,發揮華潤醫療既有的學科優勢,同時利用外延和內生的增長來培育心血管科、腦科、骨科、康復科、消化科和腫瘤科六大學科集羣,以強化核心競爭優勢、打造華潤醫療優勢學科品牌。在綜合醫院的運營方面,集團將加快推進“大專科、強綜合”的發展路徑,以現有優勢專科為基礎,持續做精專科、深化綜合醫院運營體系並提高經營效益。華潤醫療將繼續秉承“仁心仁術、康澤天下”的企業使命,成為大眾信賴、國內一流的醫療產業控股集團。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account